Skip to main content
CS Medica A/S logo

CS Medica A/S — Investor Relations & Filings

Ticker · CSMED ISIN · DK0061668225 LEI · 549300SC8KWO7JFWLN17 CO Manufacturing
Open in API
Filings indexed 4 across all filing types
Latest filing 2024-07-01 Delisting Announcement
Country DK Denmark
Listing CO CSMED

About CS Medica A/S

https://www.cs-medica.com/

CS MEDICA A/S is a MedTech company engaged in the research, development, manufacturing, and commercialization of over-the-counter (OTC) treatments. The company specializes in products containing Cannabidiol (CBD) and other cannabis compounds, targeting conditions such as pain, autoimmune disorders, and stress-related symptoms. Its portfolio, marketed under the CANNASEN® brand and also available for white-labeling, includes patented and registered medical devices and cosmetics. The company's development and manufacturing processes adhere to quality standards such as GMP and ISO 13485, with products being CE marked in compliance with medical device regulations.

Recent filings

Filing Released Lang Actions
CS MEDICA Stock Now Also Traded on XETRA
Delisting Announcement Classification · 99% confidence The document is a short news release dated July 1, 2024, announcing that CS MEDICA A/S shares are now also traded on the XETRA platform, detailing the involvement of a Designated Sponsor (Hauck Aufhäuser Lampe) to ensure liquidity. This is a specific corporate action related to stock exchange listing and trading venue expansion. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a management change (MANG). Since it announces a specific market event (listing/trading venue addition) that doesn't fit perfectly into Capital Markets Day (AGM-R), Financing (CAP), or Share Issue (SHA), it falls best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). Given the specific nature of the announcement (trading venue addition), RNS is the most appropriate fallback.
2024-07-01 English
CS MEDICA Group Achieves Complete Registration of CANNASEN CBD-Infused Medical Devices in Israel
Regulatory Filings Classification · 100% confidence The document is an 'Ad-hoc' announcement dated June 17, 2024, disclosing 'inside information' according to Article 17 MAR. The core content is the announcement of a 'Strategic Milestone Achieved' regarding the 'Complete Registration of CANNASEN® CBD-Infused Medical Devices in Israel' by CS MEDICA Group. This is a specific, material corporate event announcement, not a comprehensive periodic report (like 10-K or IR), a transcript (CT), or a formal proxy/remuneration document. It details regulatory approval success, which is a significant corporate update. Since it is a specific, material announcement that doesn't fit the definitions for ER, DIV, CAP, or MANG, and it is not a general regulatory filing fallback (RNS) but a specific operational/regulatory update, the closest fit among the provided options for a significant, non-financial, non-management change announcement is often categorized under general regulatory or corporate news. However, given the context of regulatory approval for a product, it is a specific corporate event disclosure. Since there is no specific 'Regulatory Approval Announcement' code, and it is not a standard financial report, it falls best under the general 'Regulatory Filings' (RNS) category as a mandatory disclosure under MAR, or potentially 'LTR' if viewed as a regulatory hurdle overcome, but RNS is the standard catch-all for mandatory MAR disclosures that aren't explicitly financial reports or management changes. Given the nature of the disclosure (regulatory success), RNS is the most appropriate fallback for a mandatory, non-standard report filing.
2024-06-17 English
CS MEDICA A/S Plans Stock Spin-Off and Listing of CANNORDIC A/S
Share Issue/Capital Change Classification · 95% confidence The document is an 'Ad-hoc' announcement dated June 10, 2024, disclosing 'Inside Information' according to Article 17 MAR. The core content details CS MEDICA A/S's plan to spin off and list its subsidiary CANNORDIC A/S on the German Stock Market (Intention to Float/IPO). This announcement concerns a major corporate restructuring and financing activity (raising capital via a pre-IPO phase). While it relates to a potential future listing, the immediate action described is a corporate action involving capital structure change and fundraising. The most fitting category is 'Capital/Financing Update' (CAP) due to the explicit mention of raising MDKK 45 (EUR 6 million) in the pre-IPO phase and the overall context of a spin-off intended to secure investment. It is not a formal 10-K, AR, or IR. It is an announcement of a corporate action, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains substantive details about the financing plan.
2024-06-10 English
Godkendelse af prospekt for CS medica a/s , Aktier, 13.08.2021
Capital/Financing Update Classification · 90% confidence The document is an 'EU Growth Prospectus' for CS MEDICA A/S, prepared in connection with an offer to subscribe for units (shares and warrants) and a planned listing on the Spotlight Stock Market. Prospectuses are formal legal documents required for public offerings and listings. In the provided classification schema, there is no specific 'Prospectus' category. However, such documents are regulatory filings that detail company information, financial history, and terms of the offering. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback category for a formal prospectus that does not fit into the other specific categories like 10-K or IP.
2021-08-16 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.